drugset
Drugs / PSA RNA-pulsed dendritic cell vaccine
last change Feb 2002 re-read 3 minutes ago

PSA RNA-pulsed dendritic cell vaccine

Cell therapy

Developed for
prostate cancer
Investigated by
Duke University · National Cancer Institute (NCI)

Trials 1

today NCT00004211 · Ph 1/2
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00004211 Jul 1999 → Jan 2002 prostate cancer Duke University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PSA RNA-pulsed dendritic cell vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004211 ↗
Action Deplete “Vaccines may make the body build an immune response to kill tumor cells.” NCT00004211 ↗
Modality Cell therapy “Autologous dendritic cells (DCs) transfected with mRNA encoding prostate-specific antigen (PSA) are able to stimulate potent, T cell-mediated antitumor immune responses in vitro.” PMID 11828001 ↗ Feb 2002
Route Intravenous “Patients receive prostate specific antigen (PSA) RNA pulsed autologous dendritic cells IV over 2 minutes” NCT00004211 ↗